Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyorin Pharmaceutical CoTSE:4569 74 Gross Margin % is 35.77% as of Mar. 2026, which is 26% below its 10-year median of 48.51. GuruFocus rates TSE:4569 with a GF Score™ of 74/100 and a GF Value™ of 円1,583.07 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 941 Drug Manufacturers companies, Kyorin Pharmaceutical Co ranks worse than 63.97% on this metric.
TSE:4569's Gross Margin % is ranked worse than 63.97% of 941
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs TSE:4569: 40.89
Kyorin Pharmaceutical Co had a gross margin of 35.77% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Kyorin Pharmaceutical Co was -3.10% per year.
Kyorin Pharmaceutical Co (TSE:4569) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Kyorin Pharmaceutical Co had a gross margin of 35.77% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Kyorin Pharmaceutical Co Gross Margin % Related Terms
Kyorin Pharmaceutical Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyorin Pharmaceutical Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Kyorin Pharmaceutical Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Kyorin Pharmaceutical Co (TSE:4569) has a Gross Margin % of 35.77% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Kyorin Pharmaceutical Co and its competitors. This is 26% below median its historical median of 48.51. Over the past decade, Kyorin Pharmaceutical Co's Gross Margin % has ranged from 40.89 to 55.93. According to the industry distribution chart, Kyorin Pharmaceutical Co ranks #602 out of 941 companies in the Drug Manufacturers industry, placing it in the top 64%.
Is Kyorin Pharmaceutical Co's Gross Margin % too high?
Kyorin Pharmaceutical Co's current Gross Margin % of 35.77% is 26% below median its 10-year median of 48.51. Over the past 10 years, this metric has ranged from a low of 40.89 to a high of 55.93. The Drug Manufacturers industry median Gross Margin % is 48.54. Kyorin Pharmaceutical Co's value of 35.77% is 26.3% below this industry median. Based on the distribution chart, Kyorin Pharmaceutical Co ranks #602 out of 941 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyorin Pharmaceutical Co ranks #602 out of 941 companies for Gross Margin %. This places Kyorin Pharmaceutical Co in the lower half of its industry. The industry median Gross Margin % is 48.54. Kyorin Pharmaceutical Co's value of 35.77% is 26.3% below this benchmark. Historically, Kyorin Pharmaceutical Co's own Gross Margin % has ranged from 40.89 to 55.93 over the past decade. While the company's 10-year median is 48.51 vs. the industry median of 48.54, Kyorin Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyorin Pharmaceutical Co's current Gross Margin % of 35.77% is 26.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Kyorin Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyorin Pharmaceutical Co's current Gross Margin % is 35.77%, which is 26% below median its own 10-year median of 48.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,583.07, compared to a current price of 円1,162.00 — trading 26.6% below its estimated fair value. The current Gross Margin % is 35.77%, which is 26% below median its 10-year median of 48.51 and 26.3% below the Drug Manufacturers industry median of 48.54. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current Gross Margin % is 35.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円1,162.00 is trading 26.6% below its estimated GF Value™ of 円1,583.07.
GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4569:
Gross Margin %: 35.77% (26% below median its 10-year median of 48.51)
GF Value™: 円1,583.07 vs. price of 円1,162.00 (26.6% below fair value)
Industry Position: 26.3% below the Drug Manufacturers median (#602 of 941)
No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score
Get the complete analysis for TSE:4569
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4569 has been successfully added to your 
